277 - Vital Pulp Therapy in Primary Molars: MTA vs Biodentine

Vital Pulp Therapy in Primary Molars: MTA vs Biodentine
Patel S, Sehgal T, Williams LN, Stinton NM, Frank K, Malik G
Geisinger Medical Center, Danville, PA

Purpose: To assess clinical and radiographic performance of mineral trioxide aggregate (MTA) and Biodentine as a pulpotomy and indirect pulp-capping material for maintaining the vitality in primary molars over a 24-month follow-up.

Methods: A randomized split-mouth design was employed, involving 64 pairs of carious primary molars from 49 pediatric patients. In each pair, one molar received MTA, and the contralateral molar received Biodentine for either pulpotomy or indirect pulp capping. All teeth were restored with stainless-steel crowns. Treatments were performed under general anesthesia in the operating room. Clinical and radiographic evaluations were conducted at 6-, 12-, 18-, and 24-month intervals.

Results: Preliminary data have been collected over 24 months.

Results: A total of 128 VPTs were analyzed. There was no statistically significant difference in survival between IPC and pulpotomy or between MTA- and Biodentine-treated IPCs. Only one failure occurred in a Biodentine-treated IPC on a maxillary first primary molar at 18 months. All primary molars undergoing pulpotomy experienced no failures, and aside from the single IPC failure at 18 months, all remaining treatments were successful at 24 months.

Conclusion: Biodentine is a viable alternative vital pulp therapy material.